EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
KNOWLEDGE BANK
-
Articles
Beyond Traditional Signal Detection: Advancing Pharmacovigilance Through Quantitative Epidemiology
The emergence of increasingly targeted medicines is changing the questions that pharmacovigilance must answer Antibodydrug conjugates cellular therapies genebased treatments and other advanced modalities can provide substantial therapeutic benefit yet their safety profiles may reflect complex biological mechanisms heterogeneous patient populations and delayed effects Detecting a numerical imbalanc...
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Single-cell transcriptomics and machine learning characterize LTA4H-linked lipid metabolism and inflammatory signatures in the knee osteoarthritis IPFP/synovium compartment
Knee osteoarthritis KOA is a wholejoint disease characterized by inflammation immune dysregulation and metabolic imbalance
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Biomarkers in Focus: Enhancing Clinical Research and Patient Care
Kate Williamson
Biomarkers are vital in clinical research and patient care, enabling early diagnosis, personalized treatments, and disease monitoring. This article explores their types, roles in drug development, and...
-
2
AI-Powered Pharma Supply Chains: From Visibility to Predictive Control
Lakshmi
American pharmaceutical supply chains are now extensively instrumented, yet shortages persist and two federal-facing shortage counts disagree by a factor of two. This article argues that visibility ha...
-
3
When Legacy Systems Hold Back Innovation
Lakshmi
Aging technology quietly taxes every ambition a pharmaceutical enterprise holds — slowing drug development, fracturing data, and turning each new initiative into a negotiation with the past. Yet...
-
4
FDA Drug Approval Pathways: Strategies for U.S. Pharmaceutical Companies
Kate Williamson
Navigating FDA drug approval requires more than strong science - it demands regulatory strategy from day one. This article breaks down the U.S. drug approval process, key FDA regulatory pathways (Fast...
-
5
Beyond the Chiral Blind Spot: Agentic AI and the Future of Stereochemistry-Aware Drug Discovery
Sivakumar Thanikachalam
Valliappan Kannappan
Artificial intelligence is transforming drug discovery, yet stereochemistry remains a major blind spot. This article explores how Agentic AI could integrate stereochemical reasoning across molecular d...
press releasesRead more...
Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio
Shionogi Co Ltd Head Office Osaka Japan Chief Executive Officer Isao Teshirogi PhD hereafter Shionogi announced that it has completed the acquisition of IntraBio Inc IntraBio The acquisition adds AQNEURSA levacetylleucine and additional rare disease capabilities to Shionogis growing global portfoli...
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
GSK plc LSENYSE GSK today announced the US Food and Drug Administration FDA has granted accelerated approval to Nelkarmi neladalkib for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase
Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly
Stipple Bio Inc a private biotechnology company harnessing epitopelevel precision to create targeted cancer therapies today announced that it has entered into a multitarget multimodality strategic research collaboration and license agreement with Eli Lilly and Company
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology Inc Nasdaq CRDF a clinicalstage biotechnology company targeting RASmutated cancer by leveraging PLK inhibition today announced that the US Food and Drug Administration FDA has granted Fast Track designation to onvansertib in combination
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
03 - 04
Dec 2026Infectious and Rare Diseases
Paris, France
LATEST NEWSRead more...
Erasca Partners with Bristol Myers Squibb to Evaluate ERAS-0015 Combination Therapy for Pancreatic Cancer
Clinicalstage precision oncology company Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS to evaluate its investigational drug ERAS in combination with navlimetostat BMS an investigational PRMT inhibitor developed by BMS
GATC Health and Hesperos Join Forces to Develop AI and Human-on-a-Chip Workflow for Preclinical Testing
GATC Health Corp and Hesperos Inc have entered into a strategic collaboration to develop an integrated New Approach Methodologies NAMs workflow aimed at reducing the time and cost of preclinical drug testing before human clinical trials
Novartis’ Cosentyx becomes first anti-IL-17 biologic approved for polymyalgia rheumatica
Novartis has received approval from the US Food and Drug Administration FDA for Cosentyx secukinumab mg to treat adults with polymyalgia rheumatica PMR who have not responded adequately to corticosteroids or cannot tolerate a reduction in their corticosteroid dose
Roche’s Gazyva/Gazyvaro becomes first FDA-approved treatment for primary membranous nephropathy
Roche has received approval from the US Food and Drug Administration FDA for GazyvaGazyvaro obinutuzumab to treat adults with primary membranous nephropathy pMN who are at risk of disease progression
Cyclarity Therapeutics Receives FDA Clearance for UDP-003 Clinical Trial Application in the US
Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States
Santhera Signs Distribution Agreement with SteinCares for AGAMREE in 31 Latin American and Caribbean Countries
Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States



